WuXi STA completes acquisition of Bristol Myers Squibb manufacturing facility in Switzerland

WuXi STA today announced that it has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland from Bristol Myers Squibb. WuXi STA first announced its plans to purchase the facility earlier this year. The acquisition will enhance WuXi STA’s capabilities by adding capacity to support its global partners in bringing innovative medicines to patients around the world, a statement said.

The Couvet site is the first facility in Europe for WuXi STA. Opened in 2018, this facility’s art tablet and capsule manufacturing, and packaging capabilities will provide WuXi STA’s customers more flexibility, added the statement.

It also said that by enhancing its network, WuXi STA can better support customers’ long-term needs globally, as they bring new and existing commercial manufacturing projects from their pipelines to the facility, with the capability and capacity to supply drug products to major global markets.

“We are delighted to have added the Couvet site to our global supply network and are excited to welcome its team to the WuXi STA family. Through combining resources of the Couvet site with our other facilities, we continue strengthening and broadening our capacity and capabilities to better support our global customers in delivering innovative medicines to patients in need,” said Dr Minzhang Chen, co-CEO, Wu, Xi AppTec.